Clinical Trials Logo

Recurrent Glioblastoma Multiforme (GBM) clinical trials

View clinical trials related to Recurrent Glioblastoma Multiforme (GBM).

Filter by:
  • None
  • Page 1

NCT ID: NCT00290771 Terminated - Clinical trials for Recurrent Glioblastoma Multiforme (GBM)

Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Start date: February 2006
Phase: Phase 2
Study type: Interventional

This was an investigational study to assess the objective overall response (OOR) rate (complete response [CR] + partial response [PR]) of imatinib mesylate and hydroxyurea (hydroxycarbamide) combination therapy in patients with recurrent glioblastoma multiforme (brain tumors). This study also evaluated the duration of tumor response (as per MacDonald criteria), clinical benefit, progression-free survival rate at 6 and 12 months, and the survival rate at 12 and 24 months.